RAF1 and hepatocellular carcinoma: The frequency of RAS/RAF/MAPK pathway overexpression in HCC (>90% of specimens) [17] and the typically high vascularity of hepatomas [18], [19] provide a sound rationale for the activity displayed by sorafenib against HCC.